1. Old Kent Financial Corporation, Grand Rapids, Michigan; to acquire 100 percent of the voting shares of Republic Mortgage Corporation, Salt Lake City, Utah, and Republic's 45 percent of the voting shares in World Mortgage, Logan, Utah, a Utah general partnership, and Republic's 51 percent interest in Republic Mortgage II L.C., Salt Lake City, Utah, a Utah limited liability company, and thereby engage in making and servicing mortgage loans, pursuant to §225.25(b)(1) of the Board's Regulation Y.

D. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Banterra Corp, Eldorado, Illinois; to acquire through its subsidiary, Banterra Insurance Services, Inc., Eldorado, Illinois, certain assets of Tanner Insurance Agency, Galatia, Illinois, and thereby engage in general insurance activities in a town with a population of less than 5,000, pursuant to § 225.25(b)(8)(iii)(A) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, November 20, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–28822 Filed 11–24–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Daniel P. Bednarik, Ph.D., Centers for Disease Control and Prevention (CDC): Based on an investigation conducted by the Division of Research Investigations, ORI found that Daniel P. Bednarik, Ph.D., engaged in scientific misconduct by fabricating and falsifying research data in two scientific manuscripts that were submitted for publication to the journal Nucleic Acids Research and to the journal AIDS. One paper, entitled ''Expression of the human (cytosine-5) methyltransferase is regulated by alternative mRNA splicing,'' was not accepted and the other, entitled ''Indirect evidence for an EBV–HIV hybrid virus: Human immunodeficiency virus type 1 and Epstein-Barr virus genome association,'' was withdrawn before review. Dr. Bednarik is a former employee of CDC, and the research was done while he was employed by CDC.

Dr. Bednarik and ORI have entered into a Voluntary Exclusion Agreement, which the parties agreed shall not be construed as an admission of liability or wrongdoing on the part of Dr. Bednarik. Dr. Bednarik has agreed not to appeal ORI's jurisdiction or its findings and has further voluntarily agreed:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government, as defined in 45 CFR Part 76 and 48 CFR Subparts 9.4 and 309.4 (Debarment Regulations) for a period of two (2) years, beginning on October 30, 1995;

(2) That any institution employing the Respondent be required to submit, in conjunction with each application for PHS funds or report of PHS funded research in which the Respondent is involved, a certification that the data provided by the Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application or report for a period of one (1) year following his exclusion;

(3) That any institution that submits an application for PHS support for a research project that proposes the Respondent's participation or that uses the Respondent in any capacity on PHS supported research, must concurrently submit a plan for supervision of the Respondent's duties, designed to ensure the scientific integrity of Dr. Bednarik's research, for a period of one (1) year following his exclusion; and

(4) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on October 30, 1995.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigation, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Lyle W. Bivens,

Director, Office of Research Integrity.

[FR Doc. 95–28839 Filed 11–24–95; 8:45 am]

BILLING CODE 4160–17–P

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given, pursuant to Title II of the Older Americans Act Amendments of 1987, Pub. L. 100–175 as amended by Pub. L. 102–375 and Pub. L. 103–171, that the 1995 White House Conference on Aging Policy Committee will hold a meeting on Wednesday, December 13, 1995, in Washington, DC. The general meeting will begin at 1 pm and end at approximately 4 pm. The meeting will be held in room 106 of the Dirksen Senate Office Building at C and First Streets, NE.

The general meeting of the Committee shall be open to the public. The proposed agenda includes a vote on the final report of the Conference which is to be transmitted to the President and the Congress.

Records shall be kept of all Committee proceedings and shall be available for public inspection at 501 School Street, SW., 8th Floor, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: White House Conference on Aging, 501 School Street, SW., 8th Floor, Washington, DC 20024; telephone (202) 245–7116.

Fernando M. Torres-Gill,

Assistant Secretary for Aging.

[FR Doc. 95–28848 Filed 11–24–95; 8:45 am]

BILLING CODE 4130–02–M

Health Care Financing Administration

Public Information Collection Requirements Submitted for Public Comment and Recommendations

AGENCY: Health Care Financing Administration, HHS. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summaries of proposed collections for public comment.

Type of Information Collection Request: New; *Title of Information Collection:* Medicare Carrier Provider/Supplier Enrollment Application; *Form No.:* HCFA–R–186; *Use:* This information is needed to enroll providers/suppliers by identifying them, verifying their qualifications and eligibility to participate in Medicare, and to price and pay their claims